الفهرس يوجد فقط 14 صفحة متاحة للعرض العام
 |  | from | 143 |  |  |
| | | from | 143 | | |
المستخلص
The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL tyrosine kinase. Imatinib inhibits this kinase.
This is a retrospective analysis to detect the relative efficacy of imatinib mesylate in achieving complete hematologic and molecular response for newly diagnosed patients of CML in the chronic phase who attended kasr el Aini center of radiation oncology and nuclear medicine (NEMROCK),during the period from March 2003 to Dec.2005, giving an estimate of progression-free survival and over all survival.
The standard monitoring of response includes full blood counts, clinical examination, cytogenetic examination and molecular examination by quantitative RT-PCR for BCR/ABL mRNA.
The median follow up of patients was 17.3 months.
The median dose of imatinib mesylate was 370 mg/d (range from 346 to 400 mg/d).
Q RT-PCR has provided extremely valuable for assessing and monitoring minimal residual disease after treatment with imatinib mesylate.
Imatinib induces a very rapid hematologic response (average 4 weeks) as compared to other treatment options. This response was achieved in all patients of this study.
14 patient out of 17 (82.4%) achieved molecular response, by Q RT-PCR, among the responders 41.2% > 2 log reduction, 23.5% (4 patients) showed at least 3 log reduction, 41.2% < 2 log reduction and 17.6% showed no response.
There were no correlation between the risk staging and hematologic or molecular response.
The analysis of responses was complicated by the high rate of interruption and discontinuation of treatment.
Long term of clinical significance of a reduction in the amount of BCR-ABL transcript during the period of follow up is not clear and it is too early to predict the survival advantage of this response.
No one of our patients had progressed to accelerated phase or blastic crisis.
Imatinib now seems to be the initial treatment of choice for patients with CML who do not have a suitable bone marrow donor or who are not candidates for transplantation.